^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    axitinib injectable suspension (CLS-AX)

    i
    Associations

    News

    Trials
    Company:
    Clearside Biomedical
    Drug class:
    VEGF-A inhibitor, PDGFR inhibitor
    Related drugs:
    Associations

    News

    Trials
    3ms
    ODYSSEY: Study to Evaluate Suprachoroidally Administered CLS-AX in the Treatment of Neovascular Age-Related Macular Degeneration (clinicaltrials.gov)
    P2, N=60, Completed, Clearside Biomedical, Inc. | Active, not recruiting --> Completed | Phase classification: P2b --> P2
    Trial completion • Phase classification
    |
    Eylea (aflibercept intravitreal) • axitinib injectable suspension (CLS-AX)
    over1year
    ODYSSEY: Study to Evaluate Suprachoroidally Administered CLS-AX in the Treatment of Neovascular Age-Related Macular Degeneration (clinicaltrials.gov)
    P2b, N=60, Active, not recruiting, Clearside Biomedical, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Eylea (aflibercept intravitreal) • axitinib injectable suspension (CLS-AX)